A Phase 1/2 interventional study of Durvalumab / Tremelimumab Combination Therapy in Pediatric Cancer, Solid Tumor Pediatric and Hematological Malignancies, sponsored by AstraZeneca. Active, not recruiting at 19 sites in 7 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 271st largest by enrollment of the 658 interventional ones that give a count, is one of 37 that started in 2019, is one of 81 in phase 1/2, reaches primary completion later than 27 of the 273 other live ones, and was the 435th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
821 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 276 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 37 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is close to the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 658 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 821 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 5 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 821 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.
This is a first time in pediatrics study primarily designed to evaluate the safety and tolerability of durvalumab and durvalumab in combination with tremelimumab at increasing doses in pediatric patients with advanced solid malignancies and hematological malignancies (including lymphomas) and for whom no standard of care treatments exist. Although treatment efficacy is not a primary objective of this study given its early phase nature, the patients screened for this study have no curative options and this study offers the potential of some benefit.
The study will also characterize the PK of durvalumab and durvalumab in combination with tremelimumab in children and adolescents and explore potential biological activity and immunogenicity by assessing pharmacodynamics, anti drug antibody (ADA) levels, and anti-tumor activity. The results from this trial will form the basis for decisions for potential future pediatric studies
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
This study's enrollment of 50 is close to the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 (dose finding) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are initially administered at dose level 1 and dose escalated based on results from PK modeling and tolerance to determine the RP2D. Both drugs are administered every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvavalumab for 4 doses, from cycles 2-5. (sarcoma, NB and NHL) Part 2 (dose expansion phase) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are administered at the RP2D, every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvalumab for 4 doses, from cycles 1-4. Tremelimumab may be added for 4 doses at time of progressive disease. Cohorts: solid tumors, sarcomas, NHL restricted to PMBCL and ALCL subtypes)
Drug: Durvalumab / Tremelimumab Combination Therapy
Drug pages: Durvalumab · Tremelimumab
Starting dose: durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase.
Also known as: durvalumab: Imfinzi, MEDI4736, tremelimumab: CP-675,206
Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Dose-Finding Phase: Minimum Serum Concentration (Cmin) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Dose-Finding Phase: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Dose-Finding Phase: AUC From Zero to 28 (AUC 0-28) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Dose-Finding Phase: Time to Cmax (Tmax) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Dose-Finding Phase: Apparent Terminal Elimination Half-life Associated With the Terminal Slope of the Semi-logarithmic Concentration Time Curve (t½λz) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Dose-Finding Phase: Dose-Normalized AUC (0-14) (AUC [0-14]/D) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Dose-Finding Phase: Dose-Normalized AUC (0-28) (AUC [0-28]/D) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Dose-Finding Phase: Dose-Normalized Cmax (Cmax/D) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Dose-Finding Phase: Cmax of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Dose-Finding Phase: Cmin of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Dose-Finding Phase: (AUC 0-14) of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, and Cycle 2 Day 8
Dose-Finding Phase: (AUC 0-28) of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, and Cycle 2 Day 15
Dose-Finding Phase: Tmax of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Dose-Finding Phase: T½λz of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Dose-Finding Phase: AUC (0-14)/D of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1 and Cycle 2 Day 8
Dose-Finding Phase: AUC (0-28)/D of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, and Cycle 2 Day 15
Dose-Finding Phase: Cmax/D of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Dose-Finding Phase: Number of Participants With Adverse Events (AE), Serious AE (SAE), AE Leading to Discontinuation of Durvalumab and Tremelimumab, AE of Special Interest (AESI) or AE of Possible Interest (AEPI) Related to Durvalumab and Tremelimumab
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Some AEs and higher-level terms were considered AESI or AEPIs and this list of categories were provided by the patient safety team.
Time frame: From Day 1 up to 15 months
Dose-Expansion Phase Only: Objective Response Rate (ORR)
ORR as per RECIST 1.1 was defined as the percentage of participants with at least 1 investigator-assessed visit response of complete response (CR) or partial response (PR) that was subsequently confirmed on another scan not less than 4 weeks after visit observed response. CR was defined as disappearance of all target lesions (TLs), any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met.
Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Dose-Expansion Phase Only: Duration of Response (DOR)
Duration of response was the time from the first documentation of CR/PR (which was subsequently confirmed) until the date of documented progression, or death which coincides with the progression free survival (PFS) endpoint. For participants who did not progress following a response, the DOR was censored during the PFS censoring time. It was calculated using Kaplan-Meier technique.
Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Dose-Expansion Phase Only: Best Objective Response (BOR)
BOR was calculated based on the overall visit responses from each RECIST 1.1 assessment. Categorization of BOR for solid tumors were based on RECIST 1.1 using the following response categories: CR, PR, stable disease (SD), progression of disease (PD), and not evaluable (NE). CR: disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \<10 mm. PR: 30% decrease in the sum of diameters of TLs. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD. PD: \>= 20 % increase in the sum of diameters to TLs and an increase of \>= 5 mm. NE: Only relevant if any of the TLs were not assessed or NE or had a lesion intervention at visit. Non-CR/Non-PD: Persistence of 1+ non-target lesion (s). Non-CR/non-PD was relevant to participants who did not have measurable disease at baseline.
Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Dose-Expansion Phase Only: Disease Control Rate (DCR)
DCR was defined as the percentage of participants who achieved a BOR of unconfirmed CR or PR, respectively, or who had SD. CR was defined as disappearance of all TLs, any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD.
Time frame: At 16 and 24 Weeks
Dose-Expansion Phase Only: PFS
PFS as per RECIST 1.1 was defined as the time from the date of first dose of study treatment until the date of objective disease progression or death by any cause in the absence of progression, regardless of whether the participant withdrew from study therapy or received another anti-cancer therapy prior to progression (date of PFS event or censoring - date of first dose + 1). Confidence interval was calculated using Kaplan-Meier technique.
Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Dose-Expansion Phase Only: Overall Survival (OS)
OS was defined as the time from the date of first dose of study treatment until death due to any cause regardless of whether the patient withdraws from study treatment or received another anti-cancer therapy (i.e date of death or censoring - date of first dose + 1).
Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Dose-Expansion Phase Only: Survival Rate at 12 Months and 24 Months
Survival rates were defined as the Kaplan-Meier estimate of OS at 12 and 24 months.
Time frame: At 12 and 24 Weeks
Dose-Expansion Phase: Cmax of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Dose-Expansion Phase: Cmin of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Dose-Expansion Phase: AUC (0-14) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Dose-Expansion Phase: AUC (0-28) of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Dose-Expansion Phase: Tmax of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Dose-Expansion Phase: T½λz of Durvalumab
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Dose-Expansion Phase: AUC (0-14)/D of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Dose-Expansion Phase: AUC (0-28)/D of Durvalumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Dose-Expansion Phase: Cmax/D of Durvalumab
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Dose-Expansion Phase: Cmax of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Dose-Expansion Phase: Cmin of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Dose-Expansion Phase: AUC (0-14) of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Dose-Expansion Phase: AUC (0-28) of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Dose-Expansion Phase: Tmax of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Dose-Expansion Phase: T½λz of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Dose-Expansion Phase: AUC (0-14)/D of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Dose-Expansion Phase: AUC (0-28)/D of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Dose-Expansion Phase: Cmax/D of Tremelimumab
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Dose-Finding Phase: Percentage of Participants Who Developed Detectable Anti-Drug Antibodies (ADAs)
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
Time frame: Pre-infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (durvalumab and tremelimumab), pre-infusion on Cycle 2 Day 1, Cycle 5 Day 1 and Cycle 8 Day 1 for tremelimumab
Dose-Expansion Phase: Percentage of Participants Who Developed Detectable ADAs
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. The category includes participants meeting these criteria who are ADA positive at baseline. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category includes participants meeting these criteria who are ADA positive at baseline.
Time frame: Pre-infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (durvalumab and tremelimumab) and random sample on Cycle 7 Day 1 for tremelimumab
Number of Participants With Individual Antibody Titer Measurement
Blood samples were planned to be collected for vaccine antibody titer measurements before and after planned routine immunization.
Time frame: Pre-infusion on Cycle 1 Day 1 and Cycle 4 Day 1 for durvalumab, pre-infusion on Cycle 1 Day 1, pre-infusion on Cycle 3, 4, and 8 Day 1 for tremelimumab (dose-expansion)
Median Percent Change From Baseline of Cluster of Differentiation 4+ (CD4+), CD8+, B Cells, Natural Killer (NK) Cells, and T-cell Activation With Ki67
Blood samples were collected at indicated timepoints for flow cytometry assessment. Cycle (C) and Day (D). Data collected for the flow cytometry analysis from the participants enrolled in both the dose finding and dose expansion phase were analyzed in the context of the dosing regimen received, to determine any potential differences in the immune response based on the durvalumab dose.
Time frame: Pre-dose Cycle 1 Day 8, pre-dose Cycle 2 Day 1, Cycle 2 Day 8, pre-dose Cycle 3 Day 1 (Dose-finding); Pre-dose Cycle 1 Day 1, Cycle 1 Day 8, pre-dose Cycle 2 Day 1 (Dose-expansion)
This open-label study was conducted in 2 sequential phases: a dose-finding phase (Phase I), followed by a dose-expansion phase (Phase II) in pediatric participants with advanced solid tumors, including sarcoma. Here, results for data analyzed through data cut-off date (DCO) 20-Apr-2023 have been reported.
| Milestone | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|---|---|
| Started | 7 | 11 | 3 | 8 | 11 | 10 |
| Completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 11 | 3 | 8 | 11 | 10 |
| Withdrew: Death | 6 | 8 | 3 | 7 | 8 | 7 |
| Withdrew: Moved to post-trial access program | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Study specific discontinuation criteria | 0 | 1 | 0 | 0 | 3 | 1 |
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
| micrograms/ milliliter (mcg/mL) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab | 363 ± 58.0 | 865 ± 36.0 | 275 ± 135 | 612 ± 34.2 |
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
| mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Minimum Serum Concentration (Cmin) of Durvalumab | 48.6 ± 104 | 169 ± 28.5 | 21.7 ± 34.6 | 118 ± 45.4 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
| day*mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab | 2650 ± 61.5 | 5660 ± 17.7 | 1830 ± 54.7 | 3720 ± 46.9 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
| day*mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: AUC From Zero to 28 (AUC 0-28) of Durvalumab | 3290 ± 50.1 | 8790 ± 13.5 | 2500 ± 55.4 | 6380 ± 40.1 |
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
| days | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Time to Cmax (Tmax) of Durvalumab | 0.094 (0.09 to 0.10) | 0.087 (0.00 to 0.14) | 0.09 (0.09 to 6.94) | 0.087 (0.08 to 0.09) |
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
| days | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Apparent Terminal Elimination Half-life Associated With the Terminal Slope of the Semi-logarithmic Concentration Time Curve (t½λz) of Durvalumab | 16.7 ± 47.1 | 25.3 ± 56.5 | 8.26 ± NA | 15.6 ± 23.3 |
Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Dose-Normalized AUC (0-14) (AUC [0-14]/D) of Durvalumab | 132 ± 61.5 | 189 ± 17.7 | 91.6 ± 54.7 | 124 ± 46.9 |
Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Dose-Normalized AUC (0-28) (AUC [0-28]/D) of Durvalumab | 164 ± 50.1 | 293 ± 13.5 | 125 ± 55.4 | 213 ± 40.1 |
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
| (mcg/mL)/(mg/kg) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Dose-Normalized Cmax (Cmax/D) of Durvalumab | 18.1 ± 58.0 | 28.8 ± 36.0 | 13.7 ± 135 | 20.4 ± 34.2 |
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
| mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Cmax of Tremelimumab | 19.1 ± 73.3 | 24.5 ± 44.7 | 39.2 ± 68.8 | 23.0 ± 31.7 |
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
| mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Cmin of Tremelimumab | 3.71 ± 3.75 | 3.45 ± 29.2 | — | 3.03 ± 50.3 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
| day*mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: (AUC 0-14) of Tremelimumab | 127 ± 47.3 | 160 ± 35.6 | 165 ± 7.00 | 149 ± 20.1 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
| day*mcg/mL | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: (AUC 0-28) of Tremelimumab | 235 ± 11.2 | 205 ± 22.9 | — | 208 ± 14.8 |
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
| days | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Tmax of Tremelimumab | 0.046 (0.04 to 0.08) | 0.051 (0.04 to 0.07) | 0.040 (0.04 to 0.05) | 0.046 (0.04 to 0.18) |
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
| days | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: T½λz of Tremelimumab | 16.8 ± 5.27 | 18.7 ± 20.5 | — | 31.6 ± 86.0 |
Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: AUC (0-14)/D of Tremelimumab | 127 ± 47.3 | 160 ± 35.6 | 165 ± 7.00 | 149 ± 20.1 |
Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: AUC (0-28)/D of Tremelimumab | 235 ± 11.2 | 205 ± 22.9 | — | 208 ± 14.8 |
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
| (mcg/mL)/(mg/kg) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Dose-Finding Phase: Cmax/D of Tremelimumab | 19.1 ± 73.3 | 24.5 ± 44.7 | 39.2 ± 68.8 | 23.0 ± 31.7 |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Some AEs and higher-level terms were considered AESI or AEPIs and this list of categories were provided by the patient safety team.
| Participants | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Any AE | 6 | 11 | 3 | 7 |
| Any SAE | 1 | 1 | 0 | 1 |
| AE leading to discontinuation of Durvalumab | 0 | 0 | 0 | 0 |
| AE leading to discontinuation of Tremelimumab | 0 | 1 | 0 | 0 |
| AESIs or AEPIs related to Durvalumab | 1 | 4 | 0 | 2 |
| AESIs or AEPIs related to Tremelimumab | 0 | 2 | 0 | 1 |
ORR as per RECIST 1.1 was defined as the percentage of participants with at least 1 investigator-assessed visit response of complete response (CR) or partial response (PR) that was subsequently confirmed on another scan not less than 4 weeks after visit observed response. CR was defined as disappearance of all target lesions (TLs), any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met.
| percentage of participants | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase Only: Objective Response Rate (ORR) | 0 | 11.1 |
Duration of response was the time from the first documentation of CR/PR (which was subsequently confirmed) until the date of documented progression, or death which coincides with the progression free survival (PFS) endpoint. For participants who did not progress following a response, the DOR was censored during the PFS censoring time. It was calculated using Kaplan-Meier technique.
| months | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase Only: Duration of Response (DOR) | — | 10.8 (10.8 to 10.8) |
BOR was calculated based on the overall visit responses from each RECIST 1.1 assessment. Categorization of BOR for solid tumors were based on RECIST 1.1 using the following response categories: CR, PR, stable disease (SD), progression of disease (PD), and not evaluable (NE). CR: disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \<10 mm. PR: 30% decrease in the sum of diameters of TLs. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD. PD: \>= 20 % increase in the sum of diameters to TLs and an increase of \>= 5 mm. NE: Only relevant if any of the TLs were not assessed or NE or had a lesion intervention at visit. Non-CR/Non-PD: Persistence of 1+ non-target lesion (s). Non-CR/non-PD was relevant to participants who did not have measurable disease at baseline.
| Participants | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| CR | 0 | 0 |
| PR | 0 | 1 |
| Unconfirmed complete or partial response | 0 | 0 |
| SD >= 7 weeks | 1 | 1 |
| PD | 9 | 7 |
| Not evaluable | 1 | 1 |
DCR was defined as the percentage of participants who achieved a BOR of unconfirmed CR or PR, respectively, or who had SD. CR was defined as disappearance of all TLs, any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD.
| percentage of participants | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Week 16 | 9.1 | 10.0 |
| Week 24 | 9.1 | 10.0 |
PFS as per RECIST 1.1 was defined as the time from the date of first dose of study treatment until the date of objective disease progression or death by any cause in the absence of progression, regardless of whether the participant withdrew from study therapy or received another anti-cancer therapy prior to progression (date of PFS event or censoring - date of first dose + 1). Confidence interval was calculated using Kaplan-Meier technique.
| months | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase Only: PFS | 1.7 (1.58 to 1.91) | 1.7 (0.89 to 2.76) |
OS was defined as the time from the date of first dose of study treatment until death due to any cause regardless of whether the patient withdraws from study treatment or received another anti-cancer therapy (i.e date of death or censoring - date of first dose + 1).
| months | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase Only: Overall Survival (OS) | 6.6 (2.2 to 15.8) | 6.9 (3.2 to NA) |
Survival rates were defined as the Kaplan-Meier estimate of OS at 12 and 24 months.
| percentage of participants | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| 12 Months | 25.6 (6.27 to 51.10) | 40.0 (15.94 to 63.31) |
| 24 Months | NA (NA to NA) | 30.0 (9.74 to 53.67) |
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
| mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Cmax of Durvalumab | 606 ± 27.7 | 595 ± 14.2 |
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
| mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Cmin of Durvalumab | 108 ± 29.6 | 78.3 ± 94.1 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
| day*mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-14) of Durvalumab | 4240 ± 23.2 | 3900 ± 20.0 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
| day*mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-28) of Durvalumab | 6400 ± 23.7 | 5880 ± 25.2 |
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
| days | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Tmax of Durvalumab | 0.049 (0.04 to 0.09) | 0.051 (0.04 to 0.08) |
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
| days | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: T½λz of Durvalumab | 17.4 ± 26.2 | 14.2 ± 48.6 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-14)/D of Durvalumab | 141 ± 23.2 | 130 ± 20.0 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-28)/D of Durvalumab | 213 ± 23.7 | 196 ± 25.2 |
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
| (mcg/mL)/(mg/kg) | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Cmax/D of Durvalumab | 20.2 ± 27.7 | 19.8 ± 14.2 |
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
| mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Cmax of Tremelimumab | 29.2 ± 86.0 | 23.2 ± 18.8 |
Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.
| mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Cmin of Tremelimumab | 3.91 ± 41.7 | 3.40 ± 66.2 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.
| day*mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-14) of Tremelimumab | 183 ± 65.9 | 150 ± 11.8 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.
| day*mcg/mL | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-28) of Tremelimumab | 270 ± 58.1 | 228 ± 12.4 |
Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.
| days | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Tmax of Tremelimumab | 0.049 (0.04 to 0.06) | 0.052 (0.04 to 0.07) |
Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.
| days | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: T½λz of Tremelimumab | 15.9 ± 26.2 | 15.6 ± 40.4 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-14)/D of Tremelimumab | 183 ± 65.9 | 150 ± 11.8 |
Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.
| (day*mcg/mL)/(mg/kg) | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: AUC (0-28)/D of Tremelimumab | 270 ± 58.1 | 228 ± 12.4 |
Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.
| (mcg/mL)/(mg/kg) | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Dose-Expansion Phase: Cmax/D of Tremelimumab | 29.2 ± 86.0 | 23.2 ± 18.8 |
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
| percentage of participants | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|
| Durvalumab, ADA positive at any visit | 25 | 0 | 0 | 0 |
| Durvalumab, Persistently positive | 0 | 0 | 0 | 0 |
| Durvalumab, Transiently positive | 0 | 0 | 0 | 0 |
| Tremelimumab, ADA positive at any visit | 0 | 0 | 0 | 0 |
| Tremelimumab, Persistently positive | 0 | 0 | 0 | 0 |
| Tremelimumab, Transiently positive | 0 | 0 | 0 | 0 |
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. The category includes participants meeting these criteria who are ADA positive at baseline. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category includes participants meeting these criteria who are ADA positive at baseline.
| percentage of participants | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|
| Durvalumab, ADA positive at any visit | 0 | 20 |
| Durvalumab, Persistently positive | 0 | 0 |
| Durvalumab, Transiently positive | 0 | 0 |
| Tremelimumab, ADA positive at any visit | 0 | 0 |
| Tremelimumab, Persistently positive | 0 | 0 |
| Tremelimumab, Transiently positive | 0 | 0 |
Blood samples were planned to be collected for vaccine antibody titer measurements before and after planned routine immunization.
| Participants | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants With Individual Antibody Titer Measurement | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated timepoints for flow cytometry assessment. Cycle (C) and Day (D). Data collected for the flow cytometry analysis from the participants enrolled in both the dose finding and dose expansion phase were analyzed in the context of the dosing regimen received, to determine any potential differences in the immune response based on the durvalumab dose.
| percentage of cells per cubic millimeter | Dose Expansion: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Dose Finding: Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Dose Finding: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|
| T cells CD4+ Ki67; C1D8 | 112.8 (69.2 to 352.5) | — | — |
| T cells CD4+ Ki67; C2D1 | 10.3 (-45.8 to 57.6) | 16.7 (-24.0 to 66.7) | -25.8 (-43.8 to 37.8) |
| T cells CD4+ Ki67; C2D8 | — | 153.1 (58.0 to 925.0) | 118.2 (65.1 to 215.0) |
| T cells CD4+ Ki67; C3D1 | — | -33.4 (-48.0 to -18.8) | 21.9 (-31.4 to 81.3) |
| T cells CD8+ Ki67; C1D8 | 20.0 (-25.0 to 88.9) | — | — |
| T cells CD8+ Ki67; C2D1 | -20.0 (-70.8 to 117.5) | 133.3 (-9.9 to 431.3) | -62.1 (-67.5 to 173.3) |
| T cells CD8+ Ki67; C2D8 | — | 66.7 (-35.2 to 900.0) | -40.0 (-57.0 to 318.3) |
| T cells CD8+ Ki67; C3D1 | — | 0.0 (0.0 to 0.0) | -55.4 (-73.0 to 200.0) |
| T cells CD4+; C1D8 | -12.5 (-20.5 to 2.9) | — | — |
| T cells CD4+; C2D1 | 10.1 (-15.2 to 26.2) | 6.1 (-20.2 to 45.7) | 9.2 (-16.6 to 34.9) |
| T cells CD4+; C2D8 | — | 12.8 (-6.5 to 63.8) | 16.1 (-13.2 to 52.7) |
| T cells CD4+; C3D1 | — | -12.3 (-32.6 to 8.0) | 23.0 (6.3 to 39.9) |
| T cells CD8+; C1D8 | -23.3 (-37.8 to -10.3) | — | — |
| T cells CD8+; C2D1 | 3.6 (-30.2 to 23.1) | 40.4 (-18.2 to 59.2) | 10.6 (-15.6 to 50.6) |
| T cells CD8+; C2D8 | — | 30.1 (-14.6 to 60.9) | 13.8 (-18.0 to 71.2) |
| T cells CD8+; C3D1 | — | -8.3 (-24.5 to 7.9) | 0.6 (-5.5 to 2.6) |
| B cells; C1D8 | -29.2 (-40.6 to -24.7) | — | — |
| B cells; C2D1 | 6.2 (-3.1 to 56.9) | 27.2 (-1.5 to 650.0) | -12.0 (-22.0 to 128.0) |
| B cells; C2D8 | — | 20.6 (-4.8 to 1543.8) | -8.2 (-26.2 to 43.1) |
| B cells; C3D1 | — | -2.5 (-8.6 to 3.6) | 15.7 (-24.4 to 42.1) |
| NK cells; C1D8 | -30.1 (-39.7 to 15.2) | — | — |
| NK cells; C2D1 | -25.8 (-49.2 to 55.3) | 31.0 (-1.1 to 59.6) | 32.2 (14.3 to 56.8) |
| NK cells; C2D8 | — | 7.4 (-28.1 to 75.9) | 47.4 (22.2 to 55.6) |
| NK cells; C3D1 | — | 25.9 (-9.6 to 61.4) | 43.7 (-26.9 to 77.2) |
Collected over From first dose of study treatment up to approximately 4 years (clinical DCO of 20 Apr 2023). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | 6/7 (85.7%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | 8/11 (72.7%) | 1/11 (9.1%) | 11/11 (100%) |
| Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | 7/8 (87.5%) | 1/8 (12.5%) | 7/8 (87.5%) |
| SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | 8/11 (72.7%) | 6/11 (54.5%) | 8/11 (72.7%) |
| STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | 7/10 (70%) | 3/10 (30%) | 9/10 (90%) |
| Event | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/7 | 0/11 | 0/3 | 0/8 | 3/11 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 0/11 | 0/3 | 0/8 | 0/11 | 0/10 |
| Transverse sinus thrombosisNervous system disorders | 0/7 | 0/11 | 0/3 | 1/8 | 0/11 | 0/10 |
| Pulmonary thrombosisRespiratory, thoracic and mediastinal disorders | 0/7 | 0/11 | 0/3 | 0/8 | 0/11 | 1/10 |
| ConstipationGastrointestinal disorders | 0/7 | 0/11 | 0/3 | 0/8 | 0/11 | 1/10 |
| Platelet count decreasedInvestigations | 0/7 | 0/11 | 0/3 | 0/8 | 0/11 | 1/10 |
| LaryngospasmRespiratory, thoracic and mediastinal disorders | 0/7 | 0/11 | 0/3 | 0/8 | 1/11 | 0/10 |
| Abdominal painGastrointestinal disorders | 0/7 | 0/11 | 0/3 | 0/8 | 1/11 | 0/10 |
| AscitesGastrointestinal disorders | 0/7 | 0/11 | 0/3 | 0/8 | 1/11 | 0/10 |
| ColitisGastrointestinal disorders | 0/7 | 1/11 | 0/3 | 0/8 | 0/11 | 0/10 |
| Event | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/7 | 0/11 | 2/3 | 0/8 | 1/11 | 1/10 |
| NauseaGastrointestinal disorders | 0/7 | 7/11 | 0/3 | 0/8 | 0/11 | 1/10 |
| PyrexiaGeneral disorders | 2/7 | 1/11 | 0/3 | 2/8 | 6/11 | 4/10 |
| VomitingGastrointestinal disorders | 3/7 | 2/11 | 0/3 | 3/8 | 2/11 | 2/10 |
| HeadacheNervous system disorders | 1/7 | 4/11 | 0/3 | 2/8 | 1/11 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 2/7 | 2/11 | 1/3 | 1/8 | 4/11 | 3/10 |
| Alanine aminotransferase increasedInvestigations | 0/7 | 4/11 | 1/3 | 1/8 | 2/11 | 0/10 |
| PetechiaeSkin and subcutaneous tissue disorders | 0/7 | 0/11 | 1/3 | 0/8 | 0/11 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 3/11 | 1/3 | 0/8 | 2/11 | 2/10 |
| ContusionInjury, poisoning and procedural complications | 0/7 | 0/11 | 1/3 | 1/8 | 0/11 | 0/10 |
The Full analysis set (FAS) included all participants who were assigned to treatment and received at least 1 dose of study treatment.
| Age, Customized(Participants) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Total |
|---|---|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 weeks) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Children (2-11 years) | 0 | 5 | 3 | 6 | 7 | 3 | 24 |
| Adolescents (12-17 years) | 6 | 6 | 0 | 2 | 4 | 7 | 25 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 85 years and above | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 8 | 1 | 3 | 6 | 5 | 26 |
| Male | 4 | 3 | 2 | 5 | 5 | 5 | 24 |
| Race/Ethnicity, Customized(Participants) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Black or African American | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| White | 5 | 8 | 2 | 4 | 8 | 6 | 33 |
| Other | 1 | 1 | 1 | 3 | 1 | 3 | 10 |
| Race/Ethnicity, Customized(Participants) | Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg | Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 1 | 0 | 2 | 7 |
| Not Hispanic or Latino | 6 | 9 | 2 | 7 | 11 | 8 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2019 to primary completion in Feb 2023, 47 months.
Results were first posted in Mar 2024, 1 year after primary completion.
Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 47 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab